Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sitagliptin + metformin XR
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sitagliptin + metformin XR is a fixed-dose combination oral medication used to improve glycemic control in adults with type 2 diabetes mellitus. It contains two antihyperglycemic agents with complementary mechanisms of action: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin extended-release, a biguanide. Sitagliptin increases active incretin hormone levels by inhibiting DPP-4, thereby enhancing insulin secretion and reducing glucagon release in a glucose-dependent manner. Metformin decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. The combination is indicated as an adjunct to diet and exercise for the management of type 2 diabetes[1][3][8].
- Brand names
- Janumet XRJanumetSandoz-Sitagliptin-MetforminSitagliptin-Metformin
- Other names
- sitagliptin and metformin extended-releasesitagliptin/metformin HCl extended-release
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on sitagliptin + metformin XR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sitagliptin + metformin XR.